Abstract
Aims The in-hospital mortality rate of the coronavirus disease 2019 (COVID-19) is higher in case of myocardial injury, but the underlying mechanism is unknown. We conducted a study on COVID-19 patients to determine the association of the extent of lung disease or coronary artery chest computed tomography (HRCT) variables, the Agatston coronary calcium score (CCS) and peri-coronary adipose tissue (PCAT) attenuation, with mortality.
Methods and results A single-center retrospective case series of 500 consecutive patients was collected, with chest HRCT performed as a gatekeeping-strategy in the workup of patients admitted for suspected COVID-19 to our emergency department in Northern Italy, from March 5 to March 15, 2020. Patients with laboratory-confirmed COVID-19 formed the final study group. The endpoint was in-hospital mortality at the time of final follow-up (March 30, 2020). Demographic, clinical, laboratory and HRCT data were collected from hospital electronic records, and HRCT features (CCS and PCAT attenuation) were measured post-hoc from HRCT images.
Among 500 patients with suspected COVID-19, 279 had laboratory-confirmed COVID-19 and formed the study group. Among them, 170 patients (61%) were discharged alive and 109 (39%) died. Comparing patients discharged alive with patients who died, the median age was 65 vs 77 (p<0.001), with males 56% vs 68% (p=0.061), prior cardiovascular disease 9% vs 24% (p=0.001), median D-dimer 723 vs 1083 ng/ml (p<0.001), median C-reactive protein 78 vs 148 mg/L (p<0.001), the mean CCS 17 vs 189 (p<0.001) and the median PCAT attenuation −76.4 HU vs −68.6 HU (p<0.001). In multivariable analysis, only age (p<0.001), D-dimer (p=0.041), C-reactive protein (p=0.002), HRCT lung disease extent (p=0.002) and peri-coronary adipose tissue attenuation (p<0.001) – not the Agatston CCS – were independently associated with mortality.
Conclusions Our study suggests that higher mortality in COVID-19 may be at least partly mediated by coronary artery inflammation, rather than subclinical coronary artery disease extent.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We received no funding regarding the work presented
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data referred to in the manuscript are available in the identified form, upon reasonable and motivated request to the corresponding author.
